Literature DB >> 12563700

Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years.

Berit Flatø1, Gunhild Lien, Anna Smerdel, Odd Vinje, Knut Dale, Virginia Johnston, Dag Sørskaar, Torbjørn Moum, Rafal Ploski, Øystein Førre.   

Abstract

OBJECTIVE: To describe the physical and psychosocial outcome in patients with juvenile rheumatoid arthritis (JRA), compared with subjects in the general population, and to determine patient characteristics, HLA alleles, and disease variables within the first 6 months of disease onset that predict persistent disease, joint erosions, and physical disability.
METHODS: A cohort of 268 (85%) of 316 patients with JRA first admitted to the hospital between 1980 and 1985 were examined after a median of 14.9 years (range 11.7-25.1) of disease duration. Controls matched for age, sex, and geographic region were randomly selected from the general population. Patients' medical records were retrospectively reviewed. Clinical examinations and radiographs of the hips, ankles, and affected joints were obtained. HLA-DRB1 and DPB1 alleles were determined by genotyping and HLA-B27 by serologic testing. Physical and psychosocial health status was assessed using the Short-Form Health Survey (SF-36) and the Health Assessment Questionnaire (HAQ).
RESULTS: At followup, 133 patients with JRA (50%) were in remission, 63 (24%) had developed joint erosions, and 93 (36%) had impaired physical functioning (HAQ > 0.0). Patients had greater disability, more bodily pain, and poorer general health than controls. Comparable levels of education, social function, and mental health were found, but the patients had higher rates of unemployment than controls (19% vs 7%; p < 0.001). Predictors of persistent disease and joint erosions were: young onset age and large numbers of affected joints, long duration of elevated erythrocyte sedimentation rate (ESR), and positive IgM rheumatoid factor (RF) within the first 6 months. Additionally, persistent disease was predicted by the presence of DRB1*08, and joint erosions were predicted by symmetric arthritis and DRB1*08 and HLA-B27 in combination. DRB1*01 was a predictor of joint erosions in the pauciarticular onset type (n = 163). Predictors of physical disability were: female sex, symmetric arthritis, hip joint involvement, long duration of elevated ESR and IgM RF.
CONCLUSION: Compared with healthy controls, patients with JRA had impaired physical health and lower employment rates after more than 11 years of disease duration. Elevated ESR, extensive and symmetric arthritis, positive IgM RF, DRB1*08, DRB1*01, HLA-B27 and DRB1*08 in combination, early onset, and female sex were early risk factors for an unfavorable outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12563700

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  63 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 2.  [Biomarkers for chronic inflammatory diseases].

Authors:  D Holzinger; D Föll
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

3.  [Transition clinic--it is not always a simple segue in rheumatology for adults].

Authors:  K Minden; M Niewerth; A Zink; G Ganser
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

4.  Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.

Authors:  Panayiota Nalbanti; Florentia Kanakoudi-Tsakalidou; Maria Trachana; Polyxeni Pratsidou-Gertsi; Evangelia Farmaki; Panagiotis Bamidis; Fotios Papachristou
Journal:  Rheumatol Int       Date:  2018-05-29       Impact factor: 2.631

5.  The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.

Authors:  Jenny Sadler Gallagher; Henry A Feldman; Natalie A Stokes; Marc R Laufer; Mark D Hornstein; Catherine M Gordon; Amy D DiVasta
Journal:  J Pediatr Adolesc Gynecol       Date:  2016-02-27       Impact factor: 1.814

6.  Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects.

Authors:  Megan L Krause; Jorge A Zamora-Legoff; Cynthia S Crowson; Theresa Wampler Muskardin; Thomas Mason; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2016-07-18       Impact factor: 5.532

7.  [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].

Authors:  K Minden; J Klotsche; M Niewerth; G Horneff; A Zink
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

Review 8.  [Transition from pediatric to adult rheumatological care].

Authors:  K Minden; S Schalm
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

9.  Burden and cost of illness in patients with juvenile idiopathic arthritis.

Authors:  K Minden; M Niewerth; J Listing; T Biedermann; M Schöntube; A Zink
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

10.  Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.

Authors:  Kimme L Hyrich; Sham D Lal; Helen E Foster; Judith Thornton; Navid Adib; Eileen Baildam; Janet Gardner-Medwin; Lucy R Wedderburn; Alice Chieng; Joyce Davidson; Wendy Thomson
Journal:  Rheumatology (Oxford)       Date:  2009-11-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.